27450703|t|Peripheral interactions between cannabinoid and opioid receptor agonists in a model of inflammatory mechanical hyperalgesia
27450703|a|Activation of opioid and cannabinoid receptors expressed in nociceptors induces effective antihyperalgesia. In this study, we examined whether combinations of opioid and cannabinoid receptor agonists directed at the injured site would enhance therapeutic effectiveness. Behavioral pharmacology experiments were performed to compare the effects of DAMGO, a selective agonist for μ-opioid receptor (MOR), ACPA, a specific agonist for CB1, and combinations of DAMGO and ACPA in attenuating complete Freund's adjuvant (CFA)-induced mechanical hyperalgesia in the rat hindpaw. DAMGO (1μg-1mg) or ACPA (1μg-2mg) was administered into the inflamed paw when mechanical hyperalgesia was fully developed. When administered individually, DAMGO and ACPA dose -dependently reversed the mechanical hyperalgesia. DAMGO displayed a lower ED50 value (57.4±2.49μg) than ACPA (111.6±2.18μg), but ACPA produced longer lasting antihyperalgesic effects. Combinations of DAMGO and ACPA also dose -dependently attenuated mechanical hyperalgesia, but the antihyperalgesic effects were partial and transient even at high doses. Using isobolographic analysis, we determined that combined treatment with DAMGO and ACPA produced antagonistic effects with the observed ED50 of 128.4±2.28μg. Our findings showed that MOR and CB1 agonists directed at the inflamed site effectively attenuate mechanical hyperalgesia when administered individually, but exert opposing effects when administered together. The antagonistic interactions between the two classes of drugs at the inflamed site suggest distinct mechanisms unique to peripheral nociceptors or inflamed tissue, and therefore require further studies to investigate whether the therapeutic utility of the combined drug treatments in chronic pain conditions can be optimized.
27450703	0	10	Peripheral	T082	C0205100
27450703	11	23	interactions	T169	C1704675
27450703	32	43	cannabinoid	T116,T192	C0054594
27450703	48	63	opioid receptor	T116,T192	C0034801
27450703	64	72	agonists	T121	C0243192
27450703	78	83	model	T050	C0684309
27450703	87	99	inflammatory	T046	C0021368
27450703	100	123	mechanical hyperalgesia	T184	C2936719
27450703	124	134	Activation	T043	C1514758
27450703	138	144	opioid	T116,T192	C0034801
27450703	149	170	cannabinoid receptors	T116,T192	C0054594
27450703	171	180	expressed	T045	C0597360
27450703	184	195	nociceptors	T023	C0028246
27450703	214	230	antihyperalgesia	T033	C3540840
27450703	267	279	combinations	T080	C0205195
27450703	283	289	opioid	T116,T192	C0034801
27450703	294	314	cannabinoid receptor	T116,T192	C0054594
27450703	315	323	agonists	T121	C0243192
27450703	340	347	injured	T169	C0332664
27450703	348	352	site	T082	C0205145
27450703	367	378	therapeutic	T169	C0302350
27450703	379	392	effectiveness	T080	C1280519
27450703	394	417	Behavioral pharmacology	T091	C0872109
27450703	418	429	experiments	T062	C0681814
27450703	448	455	compare	T052	C1707455
27450703	460	470	effects of	T080	C1704420
27450703	471	476	DAMGO	T116,T121	C0525773
27450703	490	497	agonist	T121	C0243192
27450703	502	519	μ-opioid receptor	T116,T192	C0066908
27450703	521	524	MOR	T116,T192	C0066908
27450703	527	531	ACPA	T109	C0767831
27450703	544	551	agonist	T121	C0243192
27450703	556	559	CB1	T116,T192	C0378126
27450703	565	577	combinations	T080	C0205195
27450703	581	586	DAMGO	T116,T121	C0525773
27450703	591	595	ACPA	T109	C0767831
27450703	599	610	attenuating	T052	C0599946
27450703	611	637	complete Freund's adjuvant	T121,T129	C0016712
27450703	639	642	CFA	T121,T129	C0016712
27450703	652	675	mechanical hyperalgesia	T184	C2936719
27450703	683	686	rat	T015	C0034693
27450703	687	694	hindpaw	T029	C0230459
27450703	696	701	DAMGO	T116,T121	C0525773
27450703	715	719	ACPA	T109	C0767831
27450703	734	746	administered	T169	C1521801
27450703	756	764	inflamed	T046	C0021368
27450703	765	768	paw	T023	C0687080
27450703	774	797	mechanical hyperalgesia	T184	C2936719
27450703	824	836	administered	T169	C1521801
27450703	851	856	DAMGO	T116,T121	C0525773
27450703	861	865	ACPA	T109	C0767831
27450703	866	870	dose	T081	C0178602
27450703	897	920	mechanical hyperalgesia	T184	C2936719
27450703	922	927	DAMGO	T116,T121	C0525773
27450703	946	956	ED50 value	UnknownType	C0678794
27450703	976	980	ACPA	T109	C0767831
27450703	1001	1005	ACPA	T109	C0767831
27450703	1030	1054	antihyperalgesic effects	T033	C3540840
27450703	1056	1068	Combinations	T080	C0205195
27450703	1072	1077	DAMGO	T116,T121	C0525773
27450703	1082	1086	ACPA	T109	C0767831
27450703	1092	1096	dose	T081	C0178602
27450703	1110	1120	attenuated	T052	C0599946
27450703	1121	1144	mechanical hyperalgesia	T184	C2936719
27450703	1154	1178	antihyperalgesic effects	T033	C3540840
27450703	1184	1191	partial	T081	C0728938
27450703	1196	1205	transient	T079	C0205374
27450703	1214	1224	high doses	T081	C0444956
27450703	1232	1255	isobolographic analysis	T059	C0022885
27450703	1285	1294	treatment	T061	C0087111
27450703	1300	1305	DAMGO	T116,T121	C0525773
27450703	1310	1314	ACPA	T109	C0767831
27450703	1324	1344	antagonistic effects	UnknownType	C0683167
27450703	1363	1367	ED50	UnknownType	C0678794
27450703	1389	1397	findings	T169	C2607943
27450703	1410	1413	MOR	T116,T192	C0066908
27450703	1418	1421	CB1	T116,T192	C0378126
27450703	1422	1430	agonists	T121	C0243192
27450703	1447	1455	inflamed	T046	C0021368
27450703	1456	1460	site	T082	C0205145
27450703	1473	1482	attenuate	T052	C0599946
27450703	1483	1506	mechanical hyperalgesia	T184	C2936719
27450703	1512	1524	administered	T169	C1521801
27450703	1543	1548	exert	T040	C0015264
27450703	1571	1583	administered	T169	C1521801
27450703	1598	1623	antagonistic interactions	UnknownType	C0678797
27450703	1651	1656	drugs	T121	C0013227
27450703	1664	1672	inflamed	T046	C0021368
27450703	1673	1677	site	T082	C0205145
27450703	1706	1712	unique	T080	C1710548
27450703	1716	1726	peripheral	T082	C0205100
27450703	1727	1738	nociceptors	T023	C0028246
27450703	1742	1750	inflamed	T046	C0021368
27450703	1751	1757	tissue	T024	C0040300
27450703	1800	1811	investigate	T169	C1292732
27450703	1824	1835	therapeutic	T169	C0302350
27450703	1836	1843	utility	T169	C3669222
27450703	1851	1859	combined	T080	C0205195
27450703	1860	1875	drug treatments	T061	C0013216
27450703	1879	1891	chronic pain	T184	C0150055
27450703	1910	1919	optimized	T052	C2698650